Stockreport

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward [Seeking Alpha]

Inozyme Pharma, Inc.  (INZY) 
PDF Results from the phase 3 ENERGY-3 study, using INZ-701 for the treatment of patients with ENPP1 Deficiency, expected in mid-2025. An expansion opportunity exists for [Read more]